Lipo-Based Vaccines as an Approach to Target Dendritic Cells for Induction of T- and iNKT Cell Responses

Autor: Dorian A. Stolk, Aram de Haas, Jana Vree, Sanne Duinkerken, Joyce Lübbers, Rieneke van de Ven, Martino Ambrosini, Hakan Kalay, Sven Bruijns, Hans J. van der Vliet, Tanja D. de Gruijl, Yvette van Kooyk

Publikováno v: Frontiers in Immunology, Vol 11 (2020)

In this study we developed a liposome-based vaccine containing palmitoylated synthetic long peptides (SLP) and alpha galactosylceramide (αGC) to specifically target dendritic cells (DC) for activation of both innate (invariant natural killer T-cells

Externí odkaz: https://doaj.org/article/c34750f04c244109b186f6110b88e981

Data from A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell–Mediated Antitumor Responses in Human B-cell Malignancies

Autor: Hans J. van der Vliet, Arnon P. Kater, Tanja D. de Gruijl, Paul W.H.I. Parren, Rob C. Roovers, Steven T. Pals, Mark-David Levin, Rieneke van de Ven, Anita G. Stam, Renate de Boer, Jana Vree, George L. Scheffer, Roeland Lameris, Iris de Weerdt

Novel T cell–based therapies for the treatment of B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and multiple myeloma (MM), are thought to have strong potential. Progress, however, has been hampered by low efficacy and high toxicit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4993802098a95dc76dd88087515bd4dc
https://doi.org/10.1158/2326-6066.c.6550482

A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell-Mediated Antitumor Responses in Human B-cell Malignancies

Autor: Hans van Vliet, Paul W. H. I. Parren, Rieneke van de Ven, Jana Vree, Roeland Lameris, Tanja D. de Gruijl, Renate de Boer, Anita G.M. Stam, George L. Scheffer, Arnon P. Kater, Steven T. Pals, Mark-David Levin, Rob C. Roovers, Iris de Weerdt

Publikováno v: Cancer immunology research, 9(1), 50-61. American Association for Cancer Research Inc.
Cancer Immunology Research, 9(1), 50-61. AMER ASSOC CANCER RESEARCH
de Weerdt, I, Lameris, R, Scheffer, G L, Vree, J, de Boer, R, Stam, A G, van de Ven, R, Levin, M-D, Pals, S T, Roovers, R C, Parren, P W H I, de Gruijl, T D, Kater, A P & van der Vliet, H J 2021, ' A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell-Mediated Antitumor Responses in Human B-cell Malignancies ', Cancer Immunology Research, vol. 9, no. 1, pp. 50-61 . https://doi.org/10.1158/2326-6066.CIR-20-0138
Cancer Immunology Research, 9(1), 50-61. American Association for Cancer Research Inc.

Novel T cell-based therapies for the treatment of B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and multiple myeloma (MM), are thought to have strong potential. Progress, however, has been hampered by low efficacy and high toxicity.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8f7629f3a109c202d9a7c6b9fe8ce0e
http://www.scopus.com/inward/record.url?scp=85100416648&partnerID=8YFLogxK

A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent antitumor response

Autor: Daniel G. Pellicci, Jérôme Le Nours, Sonja Zweegman, Jamie Rossjohn, Jana Vree, Tanja D. de Gruijl, Roeland Lameris, Hans van Vliet, Sergio M. Quiñones-Parra, Dale I. Godfrey, Adam P Uldrich, Scott J. J. Reddiex, Stephanie Gras, Richard W.J. Groen, Stewart K. Richardson, Amy R. Howell, Adam Shahine

Publikováno v: Nature Cancer, 1(11), 1054-1065. Nature Research
Lameris, R, Shahine, A, Pellicci, D G, Uldrich, A P, Gras, S, Le Nours, J, Groen, R W J, Vree, J, Reddiex, S J J, Quiñones-Parra, S M, Richardson, S K, Howell, A R, Zweegman, S, Godfrey, D I, de Gruijl, T D, Rossjohn, J & van der Vliet, H J 2020, ' A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent antitumor response ', Nature Cancer, vol. 1, no. 11, pp. 1054-1065 . https://doi.org/10.1038/s43018-020-00111-6

Antibody-mediated modulation of major histocompatibility complex (MHC) molecules, or MHC class I-like molecules, could constitute an effective immunotherapeutic approach. We describe how single-domain antibodies (VHH), specific for the human MHC clas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eea940a52a04af014f09de68a3955315
https://research.vumc.nl/en/publications/ce8fd044-e1a6-4aa8-993b-5e499a7bf788